US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

$ 17.50

5 (380) In stock

In vivo production of CAR-T cells using CD5/LNP-FAPCAR

Targeting cardiac fibrosis with engineered T cells

The Effect of Antineoplastons A10 and AS2-1 and Metabolites of

T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR

Liver fibrosis: Direct antifibrotic agents and targeted therapies

CD63 Antibody (MX-49.129.5) SCBT - Santa Cruz Biotechnology

WO2015183842A1 - Methods and compositions for preventing ischemia

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5-targeted FAP-CAR T mRNA-LNP - Google Patents

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a

In vivo production of CAR-T cells using CD5/LNP-FAPCAR